ESTRO 2024 - Abstract Book

S2323

Clinical - Urology

ESTRO 2024

Benefit of SBRT after progression was significantly reduced if compared to ARTO trial results testing upfront SBRT at castration resistance occurrence. Indeed, no significant impact was detected for patients undergoing SBRT after further progression if compared to patients shifting to following systemic treatment. Considering the positive results of ARTO trial, these data suggest that the best integrated treatment strategy relies on upfront concomitant SBRT at systemic treatment start. Waiting for further progression after AAP start may decrease benefit of local approach in oligometastatic CRPC patients.

Keywords: ARTO trial, Castrate resistant prostate cancer

References:

1) Francolini G, Gaetano Allegra A, Detti B, Di Cataldo V, Caini S, Bruni A, Ingrosso G, D'Angelillo RM, Alitto AR, Augugliaro M, Triggiani L, Parisi S, Facchini G, Banini M, Simontacchi G, Desideri I, Meattini I, Valicenti RK, Livi L; ARTO Working Group members. Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol. 2023 Sep 21:JCO2300985.

425

Mini-Oral

Comparison of death rate from cardiovascular disease: prostate cancer patients vs general population

Abdenour Nabid 1 , Nathalie Carrier 2 , André-Guy Martin 3 , Boris Bahoric 4 , Derek Wilke 5 , Eric Vigneault 3 , François Vincent 6 , Jean-Paul Bahary 7 , Marc-André Brassard 8 , Marie Duclos 9 , Peter Vavassis 10 , Redouane Bettahar 11 , Robert Archambault 12 , Sylvie Vass 8 , Thu-Van Nguyen 7 , Luis Souhami 9 1 CIUSSS de l'Estrie - CHUS, Radiation Oncology, Sherbrooke, Canada. 2 CIUSSS de l'Estrie - CHUS, Statistics, Sherbrooke, Canada. 3 Centre hospitalier universitaire de Québec, Radiation Oncology, Québec, Canada. 4 Jewish General Hospital, Radiation Oncology, Montreal, Canada. 5 Nova Scotia Cancer Center, Radiation Oncology, Halifax, Canada. 6 Centre hospitalier régional de Trois-Rivières, Radiation Oncology, Trois-Rivières, Canada. 7 Centre hospitalier universitaire de Montréal, Radiation Oncology, Montréal, Canada. 8 Centre de Santé et de Service Sociaux de Chicoutimi, Radiation Oncology, Chicoutimi, Canada. 9 McGill University Health Centre, Radiation Oncology, Montréal, Canada. 10 Hôpital Maisonneuve-Rosemont de Montréal, Radiation Oncology, Montréal, Canada. 11 Centre hospitalier régional de Rimouski, Radiation Oncology, Rimouski, Canada. 12 Hôpital de Gatineau, Radiation Oncology, Gatineau, Canada

Purpose/Objective:

The aim of this analysis is to compare the death rate from cardiovascular disease between the general population, using Statistics Canada, and patients (pts) with localized prostate cancer treated on two prospective randomized phase III trials.